Zobrazeno 1 - 7
of 7
pro vyhledávání: '"Annemarie J.M. Wijkhuijs"'
Autor:
Markus Joerger, Reno Debets, Edwin A. Basak, Daan P. Hurkmans, Cor H. van der Leest, Sebastiaan D.T. Sassen, Karlijn de Joode, Lisanne Putter, Annemarie J.M. Wijkhuijs, Birgit C.P. Koch, Marco W.J. Schreurs, Astrid A.M. van der Veldt, Joachim G.J.V. Aerts, Ron H.J. Mathijssen, Stijn L.W. Koolen
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 9, Iss 6 (2021)
Background Dosing schemes of pembrolizumab (anti-programmed cell death protein 1 monoclonal antibody) are solely based on pharmacokinetic (PK) modelling derived from phase I–III trials. The current study aimed to determine factors affecting PK and
Externí odkaz:
https://doaj.org/article/91e30061d9b14b0499f8091d36100a62
Autor:
Gert T. Verhoeven, Annemarie J.M. Wijkhuijs, Herbert Hooijkaas, Henk C. Hoogsteden, Wim Sluiter
Publikováno v:
Mediators of Inflammation, Vol 9, Iss 2, Pp 109-113 (2000)
Oxidative stress in the lung is important in the pathogenesis of COPD. Published data indicate that glucocorticoids inhibit blood cells in their capacity to produce reactive oxygen species (ROS). We investigated the effect of Fluticasone propionate (
Externí odkaz:
https://doaj.org/article/920d7cd9d0394453b53cc5af8f349034
Autor:
Julia C. Berentschot, Hemmo A. Drexhage, Daniel G. Aynekulu Mersha, Annemarie J.M. Wijkhuijs, Corine H. GeurtsvanKessel, Marion P.G. Koopmans, Jolanda Voermans, Majanka H. Heijenbrok-Kal, L. Martine Bek, Gerard M. Ribbers, Rita J.G. van den Berg-Emons, Joachim G.J.V Aerts, Willem A. Dik, Merel E. Hellemons
BackgroundA significant proportion of patients with SARS-CoV-2 infection develops long COVID with fatigue as one of the most disabling symptoms. We performed clinical and immunologic profiling of fatigued and non-fatigued long COVID patients and age
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::3a098661146aa82dacfa35f7f76a7c74
https://doi.org/10.1101/2022.09.15.22279970
https://doi.org/10.1101/2022.09.15.22279970
Autor:
Birgit C. P. Koch, Ron H.J. Mathijssen, Joachim G.J.V. Aerts, Annemarie J.M. Wijkhuijs, Sebastiaan D.T. Sassen, Reno Debets, Edwin A. Basak, Cor van der Leest, Markus Joerger, Astrid A M van der Veldt, Lisanne Putter, Karlijn de Joode, Stijn L.W. Koolen, Daan P. Hurkmans, Marco W.J. Schreurs
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 9, Iss 6 (2021)
Journal for ImmunoTherapy of Cancer, 9(6):e002344. BioMed Central Ltd.
Journal for Immunotherapy of Cancer
Journal for ImmunoTherapy of Cancer, 9(6):e002344. BioMed Central Ltd.
Journal for Immunotherapy of Cancer
BackgroundDosing schemes of pembrolizumab (anti-programmed cell death protein 1 monoclonal antibody) are solely based on pharmacokinetic (PK) modelling derived from phase I–III trials. The current study aimed to determine factors affecting PK and i
Autor:
Astrid A M van der Veldt, Esther Oomen-de Hoop, Stijn L.W. Koolen, Daan P. Hurkmans, Ilse den Besten, Edwin A. Basak, Marco W.J. Schreurs, Ron H.J. Mathijssen, Joachim G.J.V. Aerts, Annemarie J.M. Wijkhuijs, Reno Debets, Stefan Sleijfer, Sander Bins
Publikováno v:
European Journal of Cancer, 109, 12-20. Elsevier Ltd.
Introduction Nivolumab treatment is subject to large interpatient variability in both efficacy and toxicity, which may partly be explained by differences in nivolumab exposure. Exposure–response relationships in regular healthcare have not been ext
Autor:
Stijn L.W. Koolen, Marco W.J. Schreurs, Edwin A. Basak, Annemarie J.M. Wijkhuijs, Ron H.J. Mathijssen
Publikováno v:
Therapeutic Drug Monitoring, 40(5), 596-601. Lippincott Williams & Wilkins
Background: Treatment with monoclonal antibodies (mAbs) against programmed cell death protein 1 receptor is subject to high variation in treatment outcome among cancer patients. For these agents, no exposure–response (ER) relationships have been in
Autor:
Ron H.J. Mathijssen, Sander Bins, Arlette E. Odink, Annemarie J.M. Wijkhuijs, Darlene Mercieca, Tanja van Dijk, Reno Debets, Esther Oomen-de Hoop, Markus Joerger, Edwin A. Basak, Astrid Aplonia Maria Van Der Veldt, Daan P. Hurkmans, Marco W.J. Schreurs, Joachim G.J.V. Aerts, Stijn L.W. Koolen, Cor van der Leest
Publikováno v:
Journal for ImmunoTherapy of Cancer, 7(1):192. BioMed Central Ltd.
Journal for ImmunoTherapy of Cancer, Vol 7, Iss 1, Pp 1-11 (2019)
Journal for Immunotherapy of Cancer
Journal for ImmunoTherapy of Cancer, Vol 7, Iss 1, Pp 1-11 (2019)
Journal for Immunotherapy of Cancer
Background Nivolumab is currently administered in a weight-based or fixed-flat dosing regimen. Approved fixed-flat dosing regimens have been solely based on simulations from dose-finding clinical trials. For patients with non-small cell lung cancer (